产品
编 号：F761730
分子式：C17H12N6O3S
分子量：380.38
分子式：C17H12N6O3S
分子量：380.38
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 946857-84-7
产品详情
生物活性：
BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD).
体内研究：
BSc3094 (3 mg/kg; i.v.) direct intraventricular administration reduces sarkosyl-insoluble Tau.BSc3094 (0.075~1.5 mM; intraventricular administration) reduces the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%.BSc3094 reverses the pre-synaptic impairment in organotypic hippocampal slices from pro-aggregant mice, by reversing the pairedpulse depression observed in non-treated pro-aggregant Tau slices after applying a paired-pulse stimulus of the Schaffer collaterals. BSc3094 reverses the increase in Tau phosphorylation levels in rTg4510 mice down to control level. BSc3094 partially reversed the memory deficits in rTg4510 mice.Animal Model:Mice
Dosage:3 mg/kg
Administration:I.v.
Result:Direct intraventricular administration reduced sarkosyl-insoluble Tau.
Animal Model:rTg4510 mice
Dosage:0.075~1.5 mM
Administration:Intraventricular administration
Result:Reduced the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%.
BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD).
体内研究：
BSc3094 (3 mg/kg; i.v.) direct intraventricular administration reduces sarkosyl-insoluble Tau.BSc3094 (0.075~1.5 mM; intraventricular administration) reduces the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%.BSc3094 reverses the pre-synaptic impairment in organotypic hippocampal slices from pro-aggregant mice, by reversing the pairedpulse depression observed in non-treated pro-aggregant Tau slices after applying a paired-pulse stimulus of the Schaffer collaterals. BSc3094 reverses the increase in Tau phosphorylation levels in rTg4510 mice down to control level. BSc3094 partially reversed the memory deficits in rTg4510 mice.Animal Model:Mice
Dosage:3 mg/kg
Administration:I.v.
Result:Direct intraventricular administration reduced sarkosyl-insoluble Tau.
Animal Model:rTg4510 mice
Dosage:0.075~1.5 mM
Administration:Intraventricular administration
Result:Reduced the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备